The DOI matches its Crossref record; 435 of the 436 references it cites were found in a registry or an index; none of the 356 sources its claims cite is checked for support yet.
2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Open accessAbstract
Author(s): Arnett, Donna K; Blumenthal, Roger S; Albert, Michelle A; Buroker, Andrew B; Goldberger, Zachary D; Hahn, Ellen J; Himmelfarb, Cheryl Dennison; Khera, Amit; Lloyd-Jones, Donald; McEvoy, J William; Michos, Erin D; Miedema, Michael D; Muñoz, Daniel; Smith, Sidney C; Virani, Salim S; Williams, Kim A; Yeboah, Joseph; Ziaeian, Boback
Overview
CoChat Summary
TL;DR
The 2019 ACC/AHA guideline provides evidence-based recommendations for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in adults, emphasizing healthy lifestyle, team-based care, risk estimation, and selective pharmacotherapy. It recommends 10-year ASCVD risk estimation for adults 40 to 75 years of age, statin therapy for high-risk groups, a general blood pressure target of <130/80 mm Hg, and infrequent routine aspirin use.
Key findings
- The Top 10 take-home messages state that the most important way to prevent ASCVD, heart failure, and atrial fibrillation is to promote a healthy lifestyle throughout life; team-based care is effective; and adults 40 to 75 years of age should undergo 10-year ASCVD risk estimation and a clinician–patient risk discussion before starting antihypertensive therapy, a statin, or aspirin.
- Lifestyle recommendations include a diet emphasizing vegetables, fruits, nuts, whole grains, lean vegetable or animal protein, and fish while minimizing trans fats, red and processed meats, refined carbohydrates, and sweetened beverages; adults should engage in at least 150 minutes per week of accumulated moderate-intensity or 75 minutes per week of vigorous-intensity physical activity.
- For adults with type 2 diabetes mellitus, lifestyle changes are crucial; if medication is indicated, metformin is first-line, followed by consideration of a sodium-glucose cotransporter 2 inhibitor or a glucagon-like peptide-1 receptor agonist. All adults should be assessed for tobacco use at every healthcare visit and advised to quit; aspirin should be used infrequently for routine primary prevention because of lack of net benefit; statin therapy is first-line for LDL-C ≥190 mg/dL, diabetes in adults 40 to 75 years of age, or sufficient ASCVD risk; and blood pressure target should generally be <130/80 mm Hg.
- Cited evidence includes the PREDIMED trial, in which a Mediterranean diet supplemented with extra-virgin olive oil or nuts showed 30% and 28% reductions, respectively, in the combined endpoint of myocardial infarction, stroke, or cardiovascular mortality, driven largely by stroke reduction; and a UKPDS metformin substudy showing a 32% reduction in microvascular and macrovascular diabetes-related outcomes, a 39% reduction in myocardial infarction, and a 36% reduction in all-cause mortality.
Methods
- This is an ACC/AHA clinical practice guideline developed by a writing committee; evidence searches were conducted between May and July 2018 in Ovid MEDLINE, PubMed, Cochrane Library, National Institute for Health and Care Excellence, and other selected databases.
- The evidence review evaluated randomized controlled trials, systematic reviews of RCTs, meta-analyses, large US-based high-quality cohort studies, and observational studies across 9 topic areas: risk assessment, diet, exercise/physical activity, obesity and weight loss, type 2 diabetes mellitus, blood cholesterol, hypertension, smoking cessation, and aspirin use.
- Recommendations were assigned Class of Recommendation and Level of Evidence, with a modified Delphi process used to reach consensus; recommendations for cardiovascular risk, blood cholesterol, and high blood pressure were adapted from the 2017 Hypertension Clinical Practice Guideline and the 2018 Cholesterol Clinical Practice Guideline. The document was reviewed by 5 official reviewers, 3 reviewers on behalf of societies, and 23 individual content reviewers, and approved by the ACC and AHA.
Limitations
- The paper states that the pooled cohort equations have been shown to overestimate or underestimate ASCVD risk for certain subgroups; risk estimation is imperfect and based on group averages applied to individual patients; and cost/value assessments face methodological challenges including variability in costs and benefits across settings and subgroups, variability over time, and discounting that disadvantages prevention.
- The paper states evidence gaps for aspirin in adults <40 or >70 years of age, for electronic nicotine delivery systems as tobacco treatment, for reducing sedentary behavior, and notes that the cardiovascular nutrition literature is limited by a paucity of large-scale prospective randomized trials with ASCVD outcomes.
- Evident from the text: this guideline synthesizes and adapts existing evidence and prior guideline recommendations rather than generating new primary data; many recommendations rely on observational data or expert consensus where RCT evidence is limited, and supporting evidence tables are in online supplements rather than fully in the main text.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 237 Not checked · 38 Own results and interpretations
In the paper
“Increased waist circumference has been associated with increased cardiometabolic and ASCVD risk.”
§ 4. OTHER FACTORS AFFECTING CARDIOVASCULAR RISK > 4.1. Adults With Overweight and Obesity
What the sources say
- Not checked yetcites S4.1-3–S4.1-6
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Three RCTs have shown a significant reduction in ASCVD events and heart failure with use of an SGLT-2 inhibitor.”
§ 4. OTHER FACTORS AFFECTING CARDIOVASCULAR RISK > 4.2. Adults With Type 2 Diabetes Mellitus
What the sources say
- Not checked yetcites S4.2-9
- Not checked yetcites S4.2-10
- Not checked yetcites S4.2-12
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“However, 2 classes of glucose-lowering medications have recently been demonstrated to reduce CVD events in adults with T2DM and high ASCVD risk.”
§ 4. OTHER FACTORS AFFECTING CARDIOVASCULAR RISK > 4.2. Adults With Type 2 Diabetes Mellitus
What the sources say
- Not checked yetcites S4.2-9–S4.2-14
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The quality of carbohydrate intake is especially important for control of T2DM”
§ 4. OTHER FACTORS AFFECTING CARDIOVASCULAR RISK > 4.2. Adults With Type 2 Diabetes Mellitus
What the sources say
- Not checked yetcites S4.2-19
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“decreasing intake of red meat can improve glycemic control”
§ 4. OTHER FACTORS AFFECTING CARDIOVASCULAR RISK > 4.2. Adults With Type 2 Diabetes Mellitus
What the sources say
- Not checked yetcites S4.2-20
- Not checked yetcites S4.2-21
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
153 more claims
Create a free account to see all 276 claims and to verify the 356 references still open.
- It may state two separate claims as one. 92
- Probably not a substantial claim. 31
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AT plays a vital role in enhancing cardiorespiratory fitness postsurgery, which is closely linked to a reduced risk of cardiovascular and all-cause mortality (20).”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These drug classes are recommended as glucose-lowering therapy for individuals with cardiovascular disease or risk factors6,7 on the basis of randomized clinical trial evidence demonstrating a reduction in cardiovascular events (SGLT2is and GLP-1RAs)14,15,16 or suggesting cardiovascular benefit (metformin and pioglitazone).17,18”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current guideline recommendations by the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), American College of Sports Medicine (ACSM), American Association of Clinical Endocrinology (AACE), and the American Heart Association (AHA) advocate regular resistance and aerobic exercise, as well as physical activity such as increasing daily steps to avoid sed”
From The Impact of Physical Activity in Patients With Type 2 Diabetes (2025) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These lifestyle factors are all causally linked to an increased risk of the development of CVD. 5”
From Psychological Health, Well-Being, and the Mind-Heart-Body Connection: A Scientific Statement From the American Heart Association (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“AT lowers the risk of atherosclerotic cardiovascular disease, the leading cause of death in the U.S. (20).”
From The Benefits of Exercise Training in Combination With Weight Loss Therapies (2025) · cites this paper as [20]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ 4. OTHER FACTORS AFFECTING CARDIOVASCULAR RISK > 4.3. Adults With High Blood Cholesterol
“particularly for those at intermediate risk (ASCVD risk of 7.5% to ≤20%).”
§ 2. OVERARCHING RECOMMENDATIONS FOR ASCVD PREVENTION EFFORTS > 2.2. Assessment of Cardiovascular Risk
“For management of blood cholesterol, adults should be categorized as having low (<5%), borderline (5% to <7.5%), intermediate (≥7.5% to <20%), or high (≥20%) 10-year risk.”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Research works printed but not linked: 35
- Grundy, SM, Stone, NJ, Bailey, AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–1143.
- 10.1161/cir.0000000000000580 · DOI · Paper page
- 10.1161/hyp.0000000000000065 · DOI · Paper page
- DeFilippis, AP, Young, R, McEvoy, JW, et al. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort. Eur Heart J. 2017;38:598–608.
- 10.5888/pcd13.160211 · DOI · Paper page
- LeBlanc EL Patnode CD Webber EM et al. Draft evidence review for weight loss to prevent obesity-related morbidity and mortality in adults: behavioral interventions. Kaiser Permanente Research Affiliates Evidence-based Practice Center Kaiser Permanente Center for Health Research: Portland OR; 2018. AHRQ Publication No. 18-05239-EF-1. Available at: https://www.uspreventiveservicestaskforce.org/Page/Document/draft-evidence-review/obesity-in-adults-interventions1. Accessed January 5 2019.
- 10.1161/circulationaha.109.924977 · DOI · Paper page
- 10.1161/cir.0000000000000625 · DOI · Paper page
- Chou R Dana T Blazina I et al. Statin use for the prevention of cardiovascular disease in adults: a systematic review for the US Preventive Services Task Force. Report No. 14-05206-EF-2. 2016. US Agency for Healthcare Research and Quality: Rockville MD. Available at: http://www.ncbi.nlm.nih.gov/books/NBK396415. Accessed January 5 2019.
- 10.1056/nejmoa0807646 · DOI · Paper page
- 10.1016/j.jacc.2016.05.084 · DOI
- 10.1016/j.jacc.2015.07.066 · DOI · Paper page
- 10.1001/jamacardio.2017.2498 · DOI
- 10.1093/eurheartj/ehy217 · DOI · Paper page
- 10.7326/m14-1281 · DOI · Paper page
- 10.1001/jamacardio.2016.5493 · DOI · Paper page
- 10.1016/j.jcmg.2017.01.030 · DOI · Paper page
- 10.1001/jama.2016.17020 · DOI · Paper page
- 10.1016/j.jcmg.2016.03.022 · DOI
- 10.1016/j.jacc.2015.08.035 · DOI · Paper page
- 10.1001/jama.2015.7515 · DOI
- 10.1001/jamacardio.2017.0944 · DOI
- 10.1016/j.jacc.2015.10.058 · DOI · Paper page
- 10.1161/hyp.0000000000000065 · DOI · Paper page
- 10.1056/nejm200101043440101 · DOI · Paper page
- 10.1016/j.mayocp.2013.10.030 · DOI · Paper page
- 10.1016/s2468-2667(17)30003-8 · DOI · Paper page
- Tobacco Use and Dependence Guideline Panel Treating Tobacco Use and Dependence: 2008 Update. Washington, DC: US Department of Health and Human Services, 2008.
- US Institute of Medicine Committee on Secondhand Smoke Exposure and Acute Coronary Events. Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the Evidence. Washington, DC: National Academies Press. 2010. Available at: http://www.ncbi.nlm.nih.gov/books/NBK219565. Accessed January 5, 2019.
- 10.1093/eurheartj/ehw106 · DOI · Paper page
- 10.7326/m16-0577 · DOI · Paper page
- 10.1161/circoutcomes.113.000690 · DOI · Paper page
- 10.1056/nejmsa1616035 · DOI · Paper page
- 10.7326/m15-0171 · DOI · Paper page
- 10.7326/m15-2113 · DOI · Paper page
Cited by
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Self-citationHeart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Self-citationHeart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001052 · Cited by 5,987
Self-citationHeart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Cheng, S., Delling, F. N., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000950 · Cited by 5,784
Self-citationHeidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Metadata
- Authors
- Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., Michos, E. D., Miedema, M. D., Muñoz, D., Smith, S. C., Virani, S. S., Williams, K. A., Yeboah, J., & Ziaeian, B.
- Affiliations
- University of Alberta (CA)
- Lay Representative.
- ACC/AHA Task Force on Clinical Practice Guidelines Liaison.
- ACC/AHA Representative.
- Task Force Performance Measures Representative.
- ORCID
- Venue
- Circulation
- Published
- 2019-09-10
- Volume
- 140
- Issue
- 11
- Pages
- e596-e646
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- PMC
- PMC7734661
- OpenAlex
- W4210347219
- Semantic Scholar
- b75232c99217a9c07406b4e857045e20ec664720
- Cited by
- 4,536
- References
- 436
- Citations by year
- 2026: 273 · 2025: 725 · 2024: 880 · 2023: 834 · 2022: 752 · 2021: 547 · 2020: 424 · 2019: 91
- FWCI
- 74.12
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Heart Association (17SDG33630113)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- primary prevention, cardiovascular disease, cardiovascular risk factors, hypertension, hyperlipidemia, diabetes mellitus, smoking, obesity, physical inactivity, cardiovascular risk assessment, cardiovascular disease prevention
- MeSH terms
- American Heart Association, Cardiology, Cardiovascular Diseases, Humans, Primary Prevention, United States, Practice Guidelines as Topic, Advisory Committees, Research Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. https://app.cochat.ai/papers/10.1161/cir.0000000000000678
- The paper
- Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., Michos, E. D., Miedema, M. D., Muñoz, D., Smith, S. C., Virani, S. S., Williams, K. A., Yeboah, J., & Ziaeian, B. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. https://doi.org/10.1161/cir.0000000000000678
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.